SHARPE
Reported results
- Revenue for fiscal year 2026 was approximately $0.1 million, compared to $0.4 million for fiscal year 2025, a decrease of $0.3 million.
- Research and Development expenses for fiscal year 2026 were approximately $19.6 million, compared to $8.3 million for fiscal year 2025, an increase of approximately $11.3 million.
- General and Administrative expenses for fiscal year 2026 were approximately $10.6 million, compared to $10.7 million for fiscal year 2025, a decrease of approximately $0.1 million.
- Impairment of indefinite-lived intangible assets for fiscal year 2026 was approximately $5.0 million, attributable to impairment of IBIO-101; no impairments were recorded in fiscal year 2025.
- Net loss for fiscal year 2026 was $33.044 million, compared to $18.377 million for fiscal year 2025.
- Cash and cash equivalents and investments in debt securities totaled approximately $88.0 million as of June 30, 2026.
Guidance
- Cash runway extended into fiscal year 2028 based on successful financings completed in August 2025 ($100 million potential gross proceeds) and January 2026 ($26 million private placement).
Notes
Weighted-average common shares outstanding increased substantially to 104,060 thousand shares in fiscal 2026 from 10,499 thousand in fiscal 2025 due to public offering and private placement during the period. Loss per common share was $0.32 in fiscal 2026 compared to $1.75 in fiscal 2025. An impairment charge of $5.0 million was recorded for indefinite-lived intangible asset IBIO-101 in fiscal 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-08-28 (8-K, Item 2.02). Read the original filing on sec.gov.